TLPH stock icon

Talphera
TLPH

$0.92
3.25%

Market Cap: 15.6M

 

About: Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.

Employees: 15

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 4 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

11% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 9

4.89% less ownership

Funds ownership: 30.95% [Q4 2023] → 26.06% (-4.89%) [Q1 2024]

9% less funds holding

Funds holding: 33 [Q4 2023] → 30 (-3) [Q1 2024]

33% less capital invested

Capital invested by funds: $6.82M [Q4 2023] → $4.56M (-$2.27M) [Q1 2024]

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

Research analyst outlook

4 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$3
226%
upside
Avg. target
$5.25
471%
upside
High target
$6
552%
upside

4 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Ed Arce
552%upside
$6
Buy
Reiterated
15 May 2024
Maxim Group
Jason McCarthy
226%upside
$3
Buy
Initiated
6 May 2024
HC Wainwright & Co.
Ed Arce
552%upside
$6
Buy
Reiterated
7 Mar 2024
HC Wainwright & Co.
Ed Arce
552%upside
$6
Buy
Maintained
22 Jan 2024

Financial journalist opinion

Neutral
PRNewsWire
5 months ago
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering
The total committed funding is expected to provide sufficient capital to fund Talphera through a potential FDA approval of Niyad™, targeted for the first half of 2025 $16 million of total equity committed with $6 million upfront and $10 million upon the announcement of positive NEPHRO registration trial data Existing investors, Nantahala Capital and Rosalind Advisors, committed the total equity capital priced at-the-market as defined by Nasdaq rules $8 million of non-dilutive capital received from XOMA Royalty from the partial monetization of DSUVIA royalties and milestones Upon XOMA Royalty receiving a specified return, Talphera and XOMA Royalty will share in certain royalties and milestones earned from the sales of DSUVIA Abhinav Jain from Nantahala Capital Management will join the Talphera Board at closing of the equity offering SAN MATEO, Calif. , Jan. 18, 2024 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a total of $26 million of committed capital including $8 million from a partial monetization of DSUVIA royalties and milestones, $6 million of equity issued at a first closing, $10 million of committed capital upon the announcement of positive NEPHRO registration trial data, and an additional $2 million if Talphera stock trades above a specified price following the NEPHRO registration trial announcement.
Talphera Announces $26 Million Capital Commitment Through a Combination of a Non-Dilutive Royalty Monetization and Equity Offering